BIOTEST AG (BIO.DE) Stock Fundamental Analysis
FRA:BIO - Deutsche Boerse Ag - DE0005227201 - Common Stock - Currency: EUR
Taking everything into account, BIO scores 4 out of 10 in our fundamental rating. BIO was compared to 73 industry peers in the Biotechnology industry. BIO has only an average score on both its financial health and profitability. BIO has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BIO had positive earnings in the past year.
BIO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: BIO reported negative operating cash flow in multiple years.
1.2 Ratios
With a decent Return On Assets value of 1.84%, BIO is doing good in the industry, outperforming 71.23% of the companies in the same industry.
The Return On Equity of BIO (4.97%) is better than 76.71% of its industry peers.
BIO has a Return On Invested Capital of 3.84%. This is in the better half of the industry: BIO outperforms 79.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.84% | ||
| ROE | 4.97% | ||
| ROIC | 3.84% |
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BIO has a Profit Margin of 3.64%. This is in the better half of the industry: BIO outperforms 72.60% of its industry peers.
With an excellent Operating Margin value of 11.93%, BIO belongs to the best of the industry, outperforming 80.82% of the companies in the same industry.
In the last couple of years the Operating Margin of BIO has grown nicely.
BIO's Gross Margin of 30.82% is in line compared to the rest of the industry. BIO outperforms 53.42% of its industry peers.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.93% | ||
| PM (TTM) | 3.64% | ||
| GM | 30.82% |
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
BIO has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIO has about the same amount of shares outstanding.
Compared to 1 year ago, BIO has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.64 indicates that BIO is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.64, BIO is in the better half of the industry, outperforming 72.60% of the companies in the same industry.
The Debt to FCF ratio of BIO is 20.86, which is on the high side as it means it would take BIO, 20.86 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 20.86, BIO is doing good in the industry, outperforming 79.45% of the companies in the same industry.
BIO has a Debt/Equity ratio of 1.20. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of BIO (1.20) is worse than 61.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.2 | ||
| Debt/FCF | 20.86 | ||
| Altman-Z | 2.64 |
ROIC/WACC0.63
WACC6.14%
2.3 Liquidity
A Current Ratio of 5.06 indicates that BIO has no problem at all paying its short term obligations.
The Current ratio of BIO (5.06) is better than 82.19% of its industry peers.
A Quick Ratio of 2.06 indicates that BIO has no problem at all paying its short term obligations.
BIO's Quick ratio of 2.06 is in line compared to the rest of the industry. BIO outperforms 52.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.06 | ||
| Quick Ratio | 2.06 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased strongly by -74.00% in the last year.
The Revenue has grown by 10.57% in the past year. This is quite good.
The Revenue has been growing by 11.62% on average over the past years. This is quite good.
EPS 1Y (TTM)-74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.18%
Revenue 1Y (TTM)10.57%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%10.42%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 65.85 indicates a quite expensive valuation of BIO.
78.08% of the companies in the same industry are more expensive than BIO, based on the Price/Earnings ratio.
BIO's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.19.
BIO is valuated quite expensively with a Price/Forward Earnings ratio of 28.25.
Based on the Price/Forward Earnings ratio, BIO is valued cheaper than 80.82% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BIO to the average of the S&P500 Index (22.13), we can say BIO is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.85 | ||
| Fwd PE | 28.25 |
4.2 Price Multiples
78.08% of the companies in the same industry are more expensive than BIO, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BIO is valued a bit cheaper than the industry average as 79.45% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.6 | ||
| EV/EBITDA | 17.53 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a yearly dividend of 0.09%, BIO is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 7.88, BIO pays a better dividend. On top of this BIO pays more dividend than 91.78% of the companies listed in the same industry.
With a Dividend Yield of 0.09, BIO pays less dividend than the S&P500 average, which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.09% |
5.2 History
The dividend of BIO is nicely growing with an annual growth rate of 14.87%!
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
BIO pays out 6.06% of its income as dividend. This is a sustainable payout ratio.
BIO's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP6.06%
EPS Next 2YN/A
EPS Next 3YN/A
FRA:BIO (5/28/2025, 7:00:00 PM)
42.8
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.69B
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.09% |
Yearly Dividend0.04
Dividend Growth(5Y)14.87%
DP6.06%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.85 | ||
| Fwd PE | 28.25 | ||
| P/S | 2.33 | ||
| P/FCF | 52.6 | ||
| P/OCF | 27.81 | ||
| P/B | 3.19 | ||
| P/tB | 3.29 | ||
| EV/EBITDA | 17.53 |
EPS(TTM)0.65
EY1.52%
EPS(NY)1.52
Fwd EY3.54%
FCF(TTM)0.81
FCFY1.9%
OCF(TTM)1.54
OCFY3.6%
SpS18.35
BVpS13.41
TBVpS12.99
PEG (NY)0.04
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.84% | ||
| ROE | 4.97% | ||
| ROCE | 6.8% | ||
| ROIC | 3.84% | ||
| ROICexc | 4.25% | ||
| ROICexgc | 4.31% | ||
| OM | 11.93% | ||
| PM (TTM) | 3.64% | ||
| GM | 30.82% | ||
| FCFM | 4.43% |
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y111.24%
ROICexc growth 3YN/A
ROICexc growth 5Y111.29%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
F-Score5
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.2 | ||
| Debt/FCF | 20.86 | ||
| Debt/EBITDA | 5 | ||
| Cap/Depr | 70.69% | ||
| Cap/Sales | 3.95% | ||
| Interest Coverage | 4.27 | ||
| Cash Conversion | 47.88% | ||
| Profit Quality | 121.97% | ||
| Current Ratio | 5.06 | ||
| Quick Ratio | 2.06 | ||
| Altman-Z | 2.64 |
F-Score5
WACC6.14%
ROIC/WACC0.63
Cap/Depr(3y)81.86%
Cap/Depr(5y)79.06%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.18%
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.57%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%10.42%
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.15%
EBIT growth 3YN/A
EBIT growth 5Y122.17%
EBIT Next Year825%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y189.2%
FCF growth 3Y27.05%
FCF growth 5YN/A
OCF growth 1Y2355.56%
OCF growth 3Y21.56%
OCF growth 5YN/A